Central nervous system specialist Neuraxpharm Arzneimittel GmbH has partnered with Panaxia Labs Israel, to manufacture, commercialize and distribute Panaxia’s advanced medical cannabis-based pharmaceutical products in Poland.
The companies expect initial sales of the products to start in the first half of 2022, “subject to the completion and receipt of the regulatory approvals and registrations of the Polish authorities
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?